


Unknown

From: Goldstein, Jeffrey M
Sent: Tuesday, December 07, 2004 11:09 AM
To: Schwartz, Jack A
Subject: RE: Thank you for your assistance.



Jack,

After talking to you in the hall I checked my published papers and we never did publish all the receptor work done by Panlabs. However, several years ago I presented the receptor profile of quetiapine in posters at several meetings (including the insulin receptor) and the abstract for that poster was published: Goldstein JM. Pharmacology of Seroquel (ICI 204,636):an atypical clozapine-like antipsychotic. Biological Psychiatry 39:598, 1996.

Does this help?

Jeff

PS I left a copy of the poster on your table.

-----Original Message-----

From: Schwartz, Jack A
Sent: Tuesday, December 07, 2004 10:35 AM
To: Goldstein, Jeffrey M; Davis, William; Leong, Ronald
Subject: RE: Thank you for your assistance.

Jeff,

Thanks. Is the insulin receptor binding work published? If not, can we provide some of this data to Dr. Jennings?

Jack

-----Original Message-----

From: Goldstein, Jeffrey M
Sent: Tuesday, December 07, 2004 9:58 AM
To: Schwartz, Jack A; Davis, William; Leong, Ronald
Subject: RE: Thank you for your assistance.

Jack,

We have not systematically investigated the effects of quetiapine on glucose mechanisms because this was never flagged as a development issue with quetiapine. We did look at insulin receptor binding with quetiapine and NDAQ but there was no appreciable affinity so no further work was done. That said we have recently allowed a sample of quetiapine to be made available to Japanese researchers looking into pharmacologic mechanisms for insulin resistance with quetiapine, but to soon to know the results of that work. I guess the only thing we have to muddy the findings in the Dwyer paper is the lack of a signal at the insulin receptor and our clinical experience which does not support an incidence of diabetes any greater than haloperidol (Ron-is this correct?).

Jeff

-----Original Message-----

From: Schwartz, Jack A
Sent: Tuesday, December 07, 2004 7:04 AM
To: Davis, William; Leong, Ronald; Goldstein, Jeffrey M
Subject: RE: Thank you for your assistance.

Hi Bill,

I asked Jeff Goldstein for a position.

<< Message: RE: SEROQUEL: Effect on the glucose protein transport mechanism. >>

Hi Jeff,
Where do we stand with the preclinical position on the glucose protein transport mechanism?

Thanks,

jack

-----Original Message-----

From: Davis, William
Sent: Monday, December 06, 2004 6:09 PM
To: Schwartz, Jack A; Leong, Ronald
Subject: FW: Thank you for your assistance.

Hi Jack and Ron,

Have you guys been able to find any additional information that I can provide to Dr. Jennings? He probably deserves an answer pretty soon. I will be going on vacation in about a week, and thru the end of the year. I don't want him to think we forgot him.

Regards,
Bill

-----Original Message-----

From: Davis, William
Sent: Wednesday, November 17, 2004 11:54 AM
To: Leong, Ronald; Schwartz, Jack A
Cc: Davis, William; Burke, Timothy
Subject: Thank you for your assistance.

Jack and Ron,

Thank you for going above and beyond today. Your efforts make a difference in the field.

Let me know when you get some feedback on Dr Jennings's glucose transport question. As you know, he would like pre-clinical pharmacologic data supporting our position. The 2 citations in the Koller article that he mentioned are: (The discussion is on page 861 in Koller.)

43. Dwyer DS, Lu X-H, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. *Brain Res* 2003; 971:31-39
44. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. *Pharmacol Biochem Behav* 2003; 75:255-260

43.

<< File: Dwyer Brain Res 03 cytotoxicity in AAP.pdf >>

44.

(Could not find in eJournals.)

Tim,

Is the Bradley in citation #43 "Ron Bradley"- formerly of LSU - and now at Univ. of Tenn.?

Bill

William Davis, RPh, JD
Senior Medical Information Scientist - Neuroscience
AstraZeneca Pharmaceuticals LP
877-893-0390 ext. 40520
william.davis@astrazeneca.com

CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

